Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(4):309-312; doi:10.1093/jnci/91.4.309
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 4, 309-312, February 17, 1999
© 1999 Oxford University Press

NEWS

Cancer Vaccine Competition Wide Open as Agents Move Rapidly Into Clinical Arena

Tom Reynolds

With pivotal randomized trials under way, anti-melanoma agents continue to dominate the fast-growing arena of cancer vaccine research, but strategies targeting most major tumor types are moving rapidly into clinical testing.

A comparison of the basic competing vaccine designs — allogeneic versus autologous — reveals sharp disagreement among prominent investigators about what may work, and why. And, although laboratory studies are gradually sketching a clearer picture of cancer immunity that may one day favor one approach over another, the playing field in 1999 seems wide open to vastly different approaches.

Surprisingly, given the heavy tilt toward melanoma vaccine research, the first approval from the Food and Drug Administration may go to a colon cancer vaccine instead. Scientists at Intracel, a Rockville, Md., biotech firm, report that a phase III clinical trial, based at the Vrije Universiteit in Amsterdam, of the company's OncoVAX product showed the vaccine reduced recurrence by 61% . . . [Full Text of this Article]

One-Size-Fits-All

One Advantage


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?